A administração de CBD e nabilona, para a redução dos sintomas motores e cognitivos da doença de Parkinson

Abstract

Parkinson's disease (PD) occupies the 2nd place in the world ranking of the most prevalent neurodegenerative diseases in the total population, and in the last 30 years its prevalence has increased significantly. The endocannabinoid system (ECS) had its physiology revealed in the 1990s, and its action in the physiology of PD is postulated by the anti-inflammatory action of CB2R's receptors present in glial cells that make up the mesenchyme of nervous tissue and in the cells of the immune system, and by the anti-apoptotic action of the CB1R's receptors present in the nuclei and fibers of subcortical motor areas. This study aims to identify in the scientific literature evidence of the efficacy and safety of the use of cannabinoids such as CBD or nabilone, under the neuroinflammatory action of Parkinson's disease. The literature review was carried out through a search in the databases of Pubmed, Lilacs, Cochrane library, CAPES, Medline and BIREME journals, and used the following keyword descriptors: CBD, nabilone and Parkinson disease. The studies analyzed, showed that the use of cannabinoids was safe, with a low occurrence of adverse events to the use of these substances, with the use of CANABIDIOL (CBD) being the best tolerated. However, it is still inconclusive on the effectiveness of both nabilone and CBD in reducing the motor or cognitive symptoms of Parkinson's disease.